Fate Therapeutics (FATE) Other Operating Expenses (2023 - 2024)
Fate Therapeutics (FATE) posted Other Operating Expenses of $14.7 million for Q4 2024, up 836.85% on a QoQ basis from -$2.0 million in Q1 2023.
Fate Therapeutics (FATE) Other Operating Expenses (2023 - 2024) Analysis & Trends
Fate Therapeutics' Other Operating Expenses history runs 2 years deep, the most recent figure standing at $14.7 million for Q4 2024.
- Quarterly Other Operating Expenses changed N/A year-over-year to $14.7 million in Q4 2024, while the trailing twelve-month figure through Sep 2025 was $14.7 million (changed N/A YoY) and the FY2024 annual result came in at $14.7 million, up 836.85% from the prior year.
- Other Operating Expenses was $14.7 million for Q4 2024 at Fate Therapeutics, up from -$2.0 million in the prior quarter.
- Across five years, Other Operating Expenses topped out at $14.7 million in Q4 2024 and bottomed at -$2.0 million in Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | Fate Therapeutics | 288.82 Mn | 288.82 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 14.74 Mn |
| Mar 31, 2023 | -2.00 Mn |